Y. Sanz holds a BSc and PhD in Pharmacy, with an Extraordinary Award from the University of Valencia (1991; 1996). She did her postdoctoral work in the Department of Molecular Microbiology at the University of Groningen in the Netherlands (1998-99). She has performed research activities in other foreign institutions, including the Biochemistry Department at the Institute of Food Research (Reading, United Kingdom), Department of Lactic Acid Bacteria at INRA (Jouy in Josas, France), Department of Microbiology and Biotechnology at the University of Verona (Italy), Department of Immunology and Gnotobiology at the Academy of Sciences of the Czech Republic (Prague) and the Gastroenterology Division of the Medicine Department at McMaster University (Hamilton, Canada).
She is currently Professor of Research of the National Research Council (CSIC) at the Institute of Agrochemistry and Food Technology (IATA-CSIC). She was Associate Professor of the BSc in Human Nutrition and Dietetics (University of Valencia, 2005-2011) and has participated in several masters and specialization courses. These include the Master in Community and Personalised Nutrition and in Food Quality and Safety (University of Valencia), a Postgraduate course in Celiac Disease and in Functional Foods (University of Seville), a Master in Celiac Disease (Università Politecnica delle Marche, Italy) and a postgraduate course in Microbiota and Health of EAGEN (European Association for Gastroenterology, Endoscopy and Nutrition).
She was a member of the Panel on Nutrition, Dietetic Products and Allergies (NDA) of the European Food Safety Authority (EFSA) from 2009 to 2018 and as Vice-Chair of the Panel between 2012 and 2015; she has also been a member of the Guidance Review Group of the Scientific Committee and Emerging Risks of EFSA between 2012-2015 and of the Working Groups on Novel Foods and Claims in 2019. She is currently a member of the EFSA's FEEDAP Panel (2018-2023).
She regularly participates in national and international committees for the evaluation of projects and research plans (MINECO, ANEP, European Research Council Executive Agency; Alberta Heritage Foundation for Medical Research; Dutch Digestive Foundation; Danish Council for Strategic Research; INRA, German Research Foundation; Medical Research Council UK, etc.). She has also been co-chair of the working group on Nutrition and Health of the European Platform "Food for Life" (2017-now). She is, currently, member of the CSIC Committee on Ethics and Research Integrity and Collaborator of the AEI (Spanish Agency of Research) for International projects (2022-2023).
The research group ("Microbiome, Nutrition and Health") focuses on human microbiome research. It has greatly contributed to elucidating the role the gut microbiota plays in the transition from health to disease, through its interaction with the diet and the host immune and neuroendocrine systems. The pathologies investigated include from obesity to neurological conditions. The team also works on the selection of keystone intestinal bacteria that could bring health benefits and the development of dietary strategies that, through the modulation of the microbiome, reduce the disease risk. The group has expertise in epidemiological and intervention studies in humans and in advanced experimental models in vitro and in vivo and in "omics" technologies (metagenomics/transcriptomics, metabolomics, etc.). Y. Sanz has coordinated one of the largest European projects on the relationship between the human microbiome and metabolic and mental health (MyNewGut; www.mynewgut.eu) and a Marie Curie action related to obesity (miVaO) of the H2020 program. She is currently coordinating another EU project on obesity (CLIMB-OUT) of the EIT-FOOD and a Marie Curie (miVaO and MicroILCs) of H2020. She is also the principal investigator of other three European projects related to human microbiome and stress (EarlyCause) and food systems microbiomes (MicrobiomeSupport, CIRCLES, TRIBIOME) of H2020 and Horizon Europe.Y.Sanz has published over 200 (WoS) scientific papers, some in high-rated Journals (Nat Commun, Am J Clin Nut., Gigascience, Gut, Cell Metab, Gut, etc.), she has an h-index of 65 (WoS) with more than 10.000 citations (Scopus).
Selected publications of the last years:
1: Dinan TG, Stanton C, Long-Smith C, Kennedy P, Cryan JF, Cowan CSM, Cenit MC, van der Kamp JW, Sanz Y. Feeding melancholic microbes: MyNewGut recommendations on diet and mood. Clin Nutr. 2018 Nov 17. pii: S0261-5614(18)32543-3. doi:10.1016/j.clnu.2018.11.010.
2: Sanz Y, Romaní-Perez M, Benítez-Páez A, Portune KJ, Brigidi P, Rampelli S, Dinan T, Stanton C, Delzenne N, Blachier F, Neyrinck AM, Beaumont M, Olivares M, Holzer P, Günther K, Wolters M, Ahrens W, Claus SP, Campoy C, Murphy R, Sadler C, Fernández L, Kamp JV. Towards microbiome-informed dietary recommendations for promoting metabolic and mental health: Opinion papers of the MyNewGut project. Clin Nutr. 2018 Dec;37(6 Pt A):2191-2197. doi: 10.1016/j.clnu.2018.07.007.
3: Olivares M, Walker AW, Capilla A, Benítez-Páez A, Palau F, Parkhill J, Castillejo G, Sanz Y. Gut microbiota trajectory in early life may predict development of celiac disease. Microbiome. 2018 Feb 20;6(1):36. doi: 10.1186/s40168-018-0415-6.
4: Mulders RJ, de Git KCG, Schéle E, Dickson SL, Sanz Y, Adan RAH. Microbiota in obesity: interactions with enteroendocrine, immune and central nervous systems. Obes Rev. 2018 Apr;19(4):435-451. doi: 10.1111/obr.12661.
5: Agusti A, Moya-Pérez A, Campillo I, Montserrat-de la Paz S, Cerrudo V, Perez-Villalba A, Sanz Y. Bifidobacterium pseudocatenulatum CECT 7765 Ameliorates Neuroendocrine Alterations Associated with an Exaggerated Stress Response and
Anhedonia in Obese Mice. Mol Neurobiol. 2018 Jun;55(6):5337-5352. doi:10.1007/s12035-017-0768-z.
6: Romaní-Pérez M, Agusti A, Sanz Y. Innovation in microbiome-based strategies for promoting metabolic health. Curr Opin Clin Nutr Metab Care. 2017 Nov;20(6):484-491. doi: 10.1097/MCO.0000000000000419.
7: Benítez-Páez A, Sanz Y. Multi-locus and long amplicon sequencing approach to study microbial diversity at species level using the MinION™ portable nanopore sequencer. Gigascience. 2017 Jul 1;6(7):1-12. doi: 10.1093/gigascience/gix043.
8: Moya-Pérez A, Perez-Villalba A, Benítez-Páez A, Campillo I, Sanz Y. Bifidobacterium CECT 7765 modulates early stress-induced immune, neuroendocrine and behavioral alterations in mice. Brain Behav Immun. 2017 Oct;65:43-56. doi:
9: Beaumont M, Portune KJ, Steuer N, Lan A, Cerrudo V, Audebert M, Dumont F, Mancano G, Khodorova N, Andriamihaja M, Airinei G, Tomé D, Benamouzig R, Davila AM, Claus SP, Sanz Y, Blachier F. Quantity and source of dietary protein
influence metabolite production by gut microbiota and rectal mucosa gene expression: a randomized, parallel, double-blind trial in overweight humans. Am J Clin Nutr. 2017 Oct;106(4):1005-1019. doi: 10.3945/ajcn.117.158816.
10: Portune KJ, Benítez-Páez A, Del Pulgar EM, Cerrudo V, Sanz Y. Gut microbiota, diet, and obesity-related disorders-The good, the bad, and the future challenges. Mol Nutr Food Res. 2017 Jan;61(1). doi: 10.1002/mnfr.201600252.
11: Kjølbæk L, Benítez-Páez A, Gómez Del Pulgar EM, Brahe LK, Liebisch G, Matysik S, Rampelli S, Vermeiren J, Brigidi P, Larsen LH, Astrup A, Sanz Y. Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and
metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial. Clin Nutr. 2019 Feb 19. pii: S0261-5614(19)30030-5. doi: 10.1016/j.clnu.2019.01.012.
12: Rampelli S, Guenther K, Turroni S, Wolters M, Veidebaum T, Kourides Y, Molnár D, Lissner L, Benitez-Paez A, Sanz Y, Fraterman A, Michels N, Brigidi P, Candela M, Ahrens W. Pre-obese children's dysbiotic gut microbiome and unhealthy diets
may predict the development of obesity. Commun Biol. 2018 Dec 7;1:222. doi: 10.1038/s42003-018-0221-5.
- Nº Solicitud:P200703427; ES234349931 B1; PCT/ES2008/070243Título:Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. Licenciada y en ExplotaciónFecha de solicitud:Lunes, 24 Diciembre, 2007
- Nº Solicitud:P200802102; PCT/ES2009/070285Título:Bacterias y productos derivados para fortalecer las defensas y reducir el riesgo de enfermedad; LicenciadaFecha de solicitud:Martes, 8 Julio, 2008
- Nº Solicitud:ES1641.814; PCT/ES2013/070309Título:Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. LicenciadaFecha de solicitud:Martes, 7 Diciembre, 2010
- Nº Solicitud:P201230796; PCT/ES2013/070309Título:Bacteroides CECT 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas. LicenciadaFecha de solicitud:Viernes, 25 Mayo, 2012